PEN stock forecast
Our latest prediction for Penumbra, Inc.'s stock price was made on the Dec. 11, 2019 when the stock price was at 156.67$.
In the short term (2weeks), PEN's stock price should underperform the market by -4.78%. During that period the price should oscillate between -6.73% and +5.38%.
In the medium term (3months), PEN's stock price should underperform the market by -6.15%. During that period the price should oscillate between -20.37% and +12.62%.Get email alerts
About Penumbra, Inc.
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.
At the moment the company generates 523M USD in revenues.
On its last earning announcement, the company reported a profit of 1.25$ per share.
The book value per share is 12.37$
Three months stock forecastDec. 11, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|